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FAKTOR-FAKTOR RAMALAN UNTUK MORTALITI BAGI TAHUN PERTAMA 
PADA PESAKIT KEGAGALAN BUAH PINGGANG PERINGKAT AKHIR YANG 
BARU MENJALANI RAWATAN HEMODIALISIS DI KELANTAN  
ABSTRAK 
 
LATARBELAKANG: 
Secara global, bilangan pesakit buah pinggang tahap akhir (ESRD) telah menunjukkan trend 
peningkatan di kedua-dua sudah negara membangun di seluruh dunia. Kematian tahunan 
kerana ESRD di peringkat hemodialisis (HD) di Malaysia pada tahun 2015 adalah 13.8%. 
Kemandirian/Survival menyeluruh selama 5 hingga 10 tahun pada dialisis adalah 52% dan 
27%. Trend kematian dalam kalangan pesakit HD beransur menurun sejak 2 abad 
kebelakangan. Dialisis mempunyai kesan yang berat ke atas sumber kewangan dan 
penggunaannya. Kematian paling tinggi dicatatkan ketika tahun pertama permulaan 
hemodialisis. Analisa komprehensif yang telah dilaksanakan secara menyeluruh oleh 
beberapa penyelidikan terhadap pelbagai faktor risiko yang wujud semasa tahap pra-dialisis 
bagi kematian tahun pertama selepas bermulanya HD; menunjukkan keputusan yang tidak 
konsisten disebabkan kekurangan data tempatan. Kajian ini dilaksanakan bertujuan untuk 
mengenalpasti faktor prognostik yang menyumbang kepada kematian tahun pertama rawatan 
hemodialisis di kalangan pesakit baru di negeri Kelantan, Malaysia. 
 
 
 xiii 
KAEDAH: 
Kajian prospektif kohort dijalankan melibatkan 373 pesakit ESRD yang baru memulakan 
hemodialisis daripada 28 pusat hemodialisis di Kelantan daripada 1 Januari 2016 sehingga 
31 Disember 2016. Temujanji susulan subjek selepas satu tahun direkrut dilakukan sehingga 
31 Disember 2017. Kesemua pesakit yang memenuhi kriteria dimasukkan ke dalam kajian. 
Maklumat yang diperlukan ke atas pembolehubah yang terpilih diambil setiap 3 bulan 
semasa pengambilan darah dan direkodkan dalam sistem ADNAN (―Advanced Dialysis 
Nephrology Application‖). Status kemandirian/survival sehingga 31 Disember 2017 
direkodkan ke dalam borang pengumpulan data. 
 
KEPUTUSAN: 
Kemandirian/Survival terkumpul menyeluruh ESRD semasa tahun pertama memulakan HD 
di Kelantan adalah 89.5 (95% CI 86.5, 92.7) peratus. 
Berdasarkan analisis multipembolehubah Cox Proportional Hazards Regression selepas 
melaraskan beberapa pembolehubah, faktor prognostik signifikan yang memberi kesan ke 
atas risiko kematian pesakit ESRD semasa tahun pertama permulaan hemodialisis adalah 
jantina wanita (HR=2.40, 95% CI: 1.23, 4.69) and serum albumin less than 30 g/l (HR=0.93, 
95% CI: 0.89, 0.98) dan serum albumin kurang daripada 30 g/l (HR=0.93, 95% CI: 0.89, 
0.98). 
 
 xiv 
KESIMPULAN: 
Tahap kemandirian/survival pesakit ESRD semasa tahun pertama permulaan HD di 
Kelantan boleh dibandingkan dengan negara membangun yang lain. Faktor-faktor 
prognostik bebas yang signifikan yang dikenalpasti adalah lebih kurang sama dengan 
negara-negara lain. 
 
 
Kata kunci: Penyakit buah pinggang tahap akhir, hemodialisis, tahun pertama, insiden 
hemodialisis, kemandirian/survival, faktor prognostik. 
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ABSTRACT 
BACKGROUND: 
Globally the number of End-stage renal disease (ESRD) patients has been increasing in trend 
both developed and developing countries, worldwide. The annual death rate for ESRD on 
hemodialysis (HD) in Malaysia 2015 was 13.8%. The overall 5 years and 10 years survival 
on dialysis were 52% and 27% respectively. The trend for death rate among HD patients had 
gradually increased over the past 2 decades. Dialysis has a massive impact on financial 
resources and utilization. The highest incidence of mortality is found to be during the first 
year of initiation of hemodialysis. Several studies have comprehensively analyzed various 
existing risk factors during the pre-dialysis stage associated with first-year mortality after 
commencing HD; however, the results were inconsistent due to lack of local data. This study 
was carried out to identify prognostic factors that contribute to the first-year mortality in 
newly diagnosed ESRD patients in the state of Kelantan, Malaysia.  
 
METHOD: 
A prospective cohort study was conducted involving 373 ESRD patients newly initiated 
hemodialysis from 28 hemodialysis center in Kelantan from 1
st
 January 2016 to 31
st
 
December 2016. Follow up of one year after recruitment of the subjects was done until 31
st
 
December 2017. All patients who fulfilled the criteria were included in the study. The 
required information on variables of interest was taken every 3 months during blood taking 
and recorded in ADNAN (Advanced Dialysis Nephrology Application) system. The survival 
status until 31
st
 December 2017 was recorded into a data collection form.  
 xvi 
RESULTS:   
The overall cumulative survival of ESRD during the first-year initiation on HD in Kelantan 
was 89.5 (95% CI 86.5, 92.7) percent. 
Based on Cox Proportional Hazards Regression multivariable analysis after adjusting other 
variables, the significant prognostic factors that influenced the risk of mortality in ESRD 
patients during first-year of initiation of hemodialysis were female gender (HR=2.40, 95% 
CI: 1.23, 4.69) and serum albumin less than 30 g/l (HR=0.93, 95% CI: 0.89, 0.98). 
 
CONCLUSION: 
The survival rate of ESRD patients during the first-year initiation of HD in Kelantan was 
comparable with other developed countries. Significant independent prognostic factors 
identified were considered similar to other countries. 
 
Keyword: End-stage renal disease, hemodialysis, first-year, incident hemodialysis, survival, 
prognostic factor 
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CHAPTER 1: INTRODUCTION 
   
1.1 OVERVIEW OF END STAGE RENAL DISEASE 
1.1.1 Definition 
End Stage Renal Disease  
Definition of ESRD based on KDIGO Guideline on CKD. It is GFR category G5 with eGFR 
less than 15 mL/min/1.73 m2 and described as kidney failure. 
 
Source: (KDIGO Guideline on Chronic Kidney Disease, 2014) 
Figure 1.0: Stages of Chronic Kidney Disease 
 
1.1.2 Pathophysiology 
Approximately 1 million nephrons are present in each kidney, each contributing to the total 
GFR (Jacobson, 1991). Regardless of the etiology of renal injury, with progressive 
destruction of nephrons, the kidney has an innate ability to maintain GFR by hyperfiltration 
and compensatory hypertrophy of the remaining healthy nephrons. This nephron adaptability 
allows for continued normal clearance of plasma solutes. The urea and creatinine start to 
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show significant increases in plasma levels only after total GFR has decreased to 50% when 
the renal reserve has been exhausted. The plasma creatinine from a baseline value of 0.6 
mg/dL (53µmol/L) to 1.2 mg/dL (106µmol/L) in a patient, although still within the reference 
range, actually represents a loss of 50% of functioning nephron mass. The residual nephron 
hyperfiltration and hypertrophy although beneficial for the reasons noted, has been 
hypothesized to represent a major cause of progressive renal dysfunction. This is believed to 
occur because of increased glomerular capillary pressure, which damages the capillaries and 
leads initially to focal and segmental glomerulosclerosis and eventually global 
glomerulosclerosis. 
 
1.1.3 Treatment of End Stage Renal Disease 
Early nephrology referral is of extreme importance as this would significantly 
decrease morbidity and mortality (Innes et al., 1992). Timely initiation of chronic renal 
replacement therapy is imperative to prevent the uremic complications of CKD that can lead 
to significant morbidity and death.  
In general, renal replacement therapy is required when the kidneys are functioning at less 
than 10% to 15%. Renal replacement therapy is accomplished in one of the following ways: 
1. Dialysis either Hemodialysis or Peritoneal dialysis 
2. Kidney transplant either Cadaver donated or Living-relative donated 
At least 1 year is required for a renal care team to prepare patients adequately for 
dialysis. These include educating patients and their families about the different treatment 
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modalities (transplantation, hemodialysis or peritoneal dialysis), and either planning for 
noncadaveric renal transplantation or creating peritoneal or vascular access (Mendelssohn et 
al., 1999). Dialysis preferably should be initiated when the creatinine clearance falls to 5-10 
ml/min (0.08-0.17 ml/s) in asymptomatic patients or 15-20 ml/min (0.25-0.33 ml/s) in 
symptomatic patients (Churchill, 1999). 
Renal transplantation is the treatment of choice for patients with end-stage renal disease 
(Suthanthiran and Strom, 1994). Improvement in quality of life, as well as the reduction in 
mortality risk, are observed in patients with successful kidney transplantation (Schnuelle et 
al., 1998). However, renal transplantation is limited due to the shortage of suitable donors, 
the incidence of organ transplant rejection and the age and health of many ESRD patients. 
The vast majority of patients, therefore, must rely on dialysis for the remainder of their lives. 
Choice of dialysis depends on various factors namely social and family support, 
comorbid conditions, home surrounding, patient‘s independence and motivation. 
Hemodialysis removes uremia solutes and excess fluid from the blood when the kidneys 
cannot do sufficiently. The blood is drawn intravenously, sent through a dialyzer, and 
returned to the body via patient‘s arterio-venous fistula. Inside the dialyzer, the blood is 
passed over an artificial membrane that filters waste and fluid into a dialysate solution. A 
dialysate is then pumped out to a disposal tank and new dialysate is pumped in. The process 
of removing excess fluid is known as ultrafiltration. A machine is required for the purpose.  
The blood is circulated and diffused numerous times during a dialysis session; each 
circulation through the machine removes more waste and excess fluid. Hemodialysis is 
usually performed three or more times a week for 4 hours or more. 
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There are three methods of accessing the bloodstream for hemodialysis: 
1. Arteriovenous fistula (AVF) 
2. Arteriovenous graft (AVG) 
3. Temporary venous dialysis catheter 
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1.2 RESEARCH BACKGROUND  
 
Globally the number of ESRD patients has been increasing in trend both developed 
and developing countries, worldwide. The incidence of ESRD in Malaysia has been an 
increase in trend for the past 10 years. In 2001 there were 88 per million populations (pmp) 
and this had doubled to 170 pmp in 2010.  Meanwhile, the prevalence of patients with ESRD 
on dialysis had doubled from 562 pmp in 2006 to 1220 pmp in 2015 (23rd Report of the 
Malaysian Dialysis and Transplant Registry, 2015). Current projections indicate that, by 
2030, the global population of ESRD patients living on dialysis may exceed 2 million 
(Szczech and Lazar, 2004). Dialysis has a massive impact on financial resources and 
utilization. 
The annual death rate for ESRD on hemodialysis (HD) in 2015 was 13.8%. The 
overall 5 years and 10 years survival on dialysis were 52% and 27% respectively (23rd 
Report of the Malaysian Dialysis and Transplant Registry, 2015). The trend for death rate 
among HD patients had gradually increased over the past 2 decades.   
The prognosis of the patient with ESRD remains poor even though there had been 
many advances in the treatment; therefore identification of risk factors which predispose to 
mortality is important. With early identification of the risk factors, the morbidity and 
mortality of these patients going for HD will be reduced in the future. 
One of the risk factors associated with deterioration of renal function is 
cardiovascular disease. This factor is more predominant in the patient when they were 
initiated on dialysis. Based on National Registry 2015, cardiovascular disease accounted for 
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34% of all death. Death at home accounted for another 18% and the majority of this death 
was attributed to probably cardiovascular events (23rd Report of the Malaysian Dialysis and 
Transplant Registry, 2015).  
Therefore, besides treating the modifiable risk factors namely; smoking, diabetes 
mellitus (DM), hypertension (HPT), and hyperlipidemia, it is also important to treat the non-
modifiable risk factors namely iron deficiency, anemia, insulin resistance and also vitamin D 
deficiency (Wheeler et al., 2003; Wolf et al., 2007; Zoccali et al., 2003). Preventive 
measures should not only focus on disease prevention, but also in modifying disease 
outcomes. To improve patient‘s survival and quality of life on dialysis therapy, it is 
important to modify these risk factors (Anand et al., 2011; Mapes et al., 2003; Richards et 
al., 2007). 
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1.3 RATIONALE OF THE STUDY 
 
The risk of mortality among patients on HD is high and it varies among patients. 
There is no tool that is widely available for use to predict the mortality. Availability of a tool 
or predictive model which is able to stratify risk of mortality would be helpful for HD 
centers. This model will be able to classify patients into high, moderate and low risk. With 
this, dialysis providers can have an overview of types of patients that they are dealing with. 
This tool can also be used in the future study and help to identify suitable dialysis 
prescriptions or medications. This will help in providing clinical evidence in our clinical 
practice. This ‗risk-stratification-tool' could either be used as a clinical score or embedded in 
computer-based management systems. 
Data in South East Asia population is also lacking with the nearest data available 
being Singapore. 
Patient variables that have a significant impact on mortality were age, gender, 
primary renal disease, dialysis modality, body mass index (BMI), diastolic blood pressure 
and the presence of cardiovascular disease. The biochemical variables associated with a 
significant risk factor for mortality were serum albumin, serum cholesterol, hemoglobin, 
calcium, calcium phosphate product, phosphate and hepatitis B status (23rd Report of the 
Malaysian Dialysis and Transplant Registry, 2015). 
This study intends to describe the demographic profile of newly diagnosed HD 
patients within their first year of treatment focusing on mortality among them. It will 
determine the risk factors associated with early death among the Kelantan population during 
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the first year of dialysis. Risk factors assessed include patient's demography, co-morbidities, 
and several laboratory parameters. This study will then further analyze the significance of 
each parameter in relation to one-year mortality.   
Determination of these key predictors of early mortality will enable formulation of 
an effective risk prediction scoring system for clinical use in improving and reducing 
mortality of ESRD initiated on HD. Careful selection of patients for HD based on a 
predictive scoring system can improve the mortality rate of HD patients and ensure optimal 
utilization of public resources.  
Besides, this will create an opportunity for intervention for those modifiable risk 
factors such as HPT, DM, and renal bone chemistry. 
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 CHAPTER 2: LITERATURE REVIEW 
 
2.1 REGIONAL PREVALENCE AND PREVIOUS LOCAL STUDIES  
The equivalent incidence and prevalence of patients on dialysis were 249 and 1,220 pmp in 
2015. 6479 new HD cases were reported. The total number of HD patients increased to 
33,456 giving a prevalence rate of 1097 pmp. The dialysis treatment rate exceeded 200 pmp 
for all states in Malaysia in 2015, 207 pmp for Kelantan. 
Data were based on Malaysian Dialysis and Transplant Registry 2015 and there were no 
previous local studies done. 
 
2.2 INCIDENCE OF FIRST YEAR MORTALITY AND CAUSE OF DEATH 
The highest incidence of mortality is found to be during the first year of initiation of 
HD. This is proven by few studies which were conducted throughout various countries 
around the world over the period of 2001 to 2010 (Bradbury et al., 2007; Cherukuri and 
Bhandari, 2009; Chua et al., 2014; Lukowsky et al., 2012; Wagner et al., 2011). 
Based on Malaysian Dialysis and Transplant Registry 2015, patient survival by year 
of starting dialysis remained unchanged over the last 10 years with a 1 year and 5 years 
patient survival 86-88% and 50-53% respectively. Cardiovascular events remained the main 
cause of death accounted 34% for all death. The mean patient survival at 1 year (adjusted for 
age and diabetes) among HD centers for the 2006-2014 cohort was 91.4%. There was 
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marked center variation (23rd Report of the Malaysian Dialysis and Transplant Registry, 
2015). 
In 2002, a study was carried out in the UK and it was found that 56% of patient 
passed away during the first year of initiation of HD. Death was attributed to either vascular 
disease or infection accounted for the majority of them (Cherukuri and Bhandari, 2009). 
This was supported by another earlier study conducted in the same hospital in the year 2001 
to 2002. The mortality rate was 60% and this was made up of vascular disease and sepsis 
(Browne et al., 2014). 
Subsequently, a study conducted in Europe, Japan, United States, Australia, New 
Zealand, and Canada, and other European countries from 2002 to 2004. From this study, 
there were 4802 newly diagnosed ESRD initiated on HD patients, and risk for death was 
elevated during the first 120 days compared with 121 to 365 days (27.5 versus 21.9 deaths 
per 100 person-years; P=0.002). The main cause of death was cardiovascular-related deaths 
(Bradbury et al., 2007).  
Another study also had a similar finding where mortality was high in the first 6 
months, especially during 1st 2 months. This study was conducted in the United States from 
2001 to 2006 (Lukowsky et al., 2012). 
Singapore had conducted a study from 2005 to 2010, and of 983 patients, 66 (6.7%) 
died within 90 days, and a further 103 (10.5%) died after 90 days to within one year from 
dialysis initiation. The incidence of first-year mortality was 17.2%. The majority of known 
causes of death in the first year were attributed to major adverse cardiac events and 
pneumonia which accounted for >30% of deaths (Chua et al., 2014). 
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2.3 FACTORS THAT CONTRIBUTE TO FIRST YEAR MORTALITY 
 
Several studies have comprehensively analyzed various existing risk factors during 
the pre-dialysis stage associated with first-year mortality after commencing HD; however, 
the results were inconsistent. 
Patient variables that had a significant impact on mortality were age, gender, primary 
renal disease, dialysis modality, BMI, diastolic blood pressure and the presence 
cardiovascular disease. The biochemical variables associated with a significant risk factor 
for mortality were serum albumin, serum cholesterol, hemoglobin, calcium, calcium 
phosphate product, phosphate and hepatitis B status (23rd Report of the Malaysian Dialysis 
and Transplant Registry, 2015). 
From 2002 to 2004, several studies were conducted in UK and US to study different 
factors attribute to mortality during the first year of initiation of HD. 
A significant proportion of mortality occurred in the first year (56%). The patients 
who died in the first year had lower eGFR and hemoglobin levels. This group was also older 
with higher calcium phosphate products. Patients who had a significantly worse mean of 
survival periods while on dialysis are patients who had vascular disease, DM and in the 
highest quartile of calcium phosphate product (Cherukuri and Bhandari, 2009). 
Bradbury et al. identified older age, catheter vascular access, albumin <35, 
phosphorus <1.0, cancer and congestive heart failure as mortality risk factors (Bradbury et 
al., 2007). 
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Older age, white race, diabetes as a cause of ESRD and HD treatment were 
independently associated with an increased risk of all-cause mortality in a study done in the 
UK. Laboratory variables (hemoglobin, serum albumin, creatinine, calcium) and more 
specific factors, for example, cardiac function or biomarkers, such as C-reactive protein 
(CRP), adiponectin or N-terminal pro b-type natriuretic peptide (NT-proBNP) have found to 
be associated with mortality in ESRD patients (Wagner et al., 2011). 
A study was conducted in Singapore to examine patient comorbidities and 
biochemistry prior to dialysis initiation and its relationship to mortality. Older age, DM, 
IHD, cerebral vascular accident (CVA), peripheral vascular diseases (PVD) were 
significantly associated with mortality during the first year. These patients also had a low 
left ventricular ejection fraction (LVEF), low serum albumin, high eGFR, serum urea, 
alkaline phosphatase (ALP), and uric acid (Chua et al., 2014). 
Stevens et al. found that serum phosphate, after adjusting for demographic, dialysis 
type and adequacy, hemoglobin, albumin, independently predicted mortality. When 
combinations of parameters were modeled, the combinations of high serum phosphate and 
calcium with high intact parathyroid hormone (iPTH) and low iPTH had highest risks for 
mortality as compared with the combination of high iPTH with normal serum calcium and 
phosphate that had the lowest mortality. 
An analysis done in East Yorkshire showed that high calcium phosphate product, 
DM, vascular disease (such as peripheral vascular disease), older age, low hemoglobin and 
lower eGFR at initiation of dialysis are predictive of mortality (Browne et al., 2014). 
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Lukowsky et al. examined mortality patterns and predictors during the first several 
months of hemodialysis treatment in 18,707 incident patients since the first week of HD 
therapy and estimated the population attributable fractions for selected time periods in the 
first 24 months from 2001 to 2006. Highest mortality occurred during months 1 and 2, and 
mortality rates decreased over periods of 7 months. Early death was associated with more 
advanced age, a higher proportion of central venous catheters (CVC), and higher prevalence 
of cardiovascular diseases. Among laboratory parameters, serum levels of albumin, 
hemoglobin, and calcium were also predictors of 2-year mortality. 
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2.3.1 PATIENTS VARIABLES 
2.3.1.1 Age  
Age at initiation of dialysis had a significant impact on early mortality. Patients who died 
within 90 days of initiation of dialysis were significantly older p<0.001(Chua et al., 2014). 
A study from UK Renal National Registry cohort also support these findings (Wagner et al., 
2011). In another separate study conducted in United Kingdom, those aged greater than 65 
years had a mean survival time of 51 months compared to those less than 65 years who had a 
mean survival of 85 months (p=0.001)(Browne et al., 2014) In United States, age >75 years 
was found to be significantly associated with high risk of mortality during first 120 days 
(Bradbury et al., 2007). 
 
2.3.1.2 Co-morbid 
Prevalence of diabetes mellitus is increasing among the patients with chronic kidney disease 
(CKD) (Whaley-Connell et al., 2008). It represents a strong cardiovascular risk factor and a 
risk factor for mortality in both the general population and patients with ESRD (Brunner et 
al., 1988; Chantrel et al., 1999). Diabetic patients had a high risk of mortality compared to 
non-diabetics (Brunner et al., 1988). The 5-year survival rate for patients with DM is 47% 
vs. 63% without DM (p=0.03) (Cherukuri and Bhandari, 2009). A study conducted in 
Singapore also showed similar result p=0.04 (Chua et al., 2014). Another study conducted in 
the UK showed that patients with DM had a cumulative survival of 22% compared to 31% 
without DM (p=0.03) (Browne et al., 2014).  
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2.3.2 BIOCHEMICAL VARIABLES 
2.3.2.1 Haemoglobin 
Anemia is an important complication of chronic kidney disease (CKD) and it 
contributes significantly to symptoms burden of CKD. 
Hemoglobin levels vary substantially over time in hemodialysis patients, and this 
variability may portend poor outcomes. For a given patient, hemoglobin concentration over 
time can be described by absolute levels, rate of change, or by the difference between 
observed level and expected level based on the preceding trend (i.e., seemingly random 
variability). Survival analyses indicated that each 1g/dl increase in the residual standard 
deviation was associated with a 33% increase in rate of death. It was concluded that greater 
hemoglobin variability is independently associated with higher mortality (Yang et al., 2007). 
This was supported by another study where they found that mortality was greatest in 
patients who had experienced low hemoglobin levels for ≥3 months. The authors suggest 
that the number of months that the patient's hemoglobin is below the target level might be 
a better predictor of mortality than variability itself (Gilbertson et al., 2008). 
There were controversies regarding the optimal hemoglobin target in the patient 
undergoing hemodialysis. Low hemoglobin was associated with high mortality (Messana et 
al., 2009; Servilla et al., 2009). Based on UK Renal registry data from 2007, 58% of patients 
started dialysis with a hemoglobin level of <10g/dl (Richardson et al., 2009). Cherukuri et al 
found a similar finding where 68% of patients started on dialysis with hemoglobin 
concentration <10g/dl. Early mortality was increased in patients with this hemoglobin level, 
however, in the longer term; there was no significant effect on mortality. It was proposed 
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that this may possibly due to anemia management improving on dialysis (Cherukuri and 
Bhandari, 2009).  
 
2.3.2.2 Alkaline phosphatase (ALP) 
Raised ALP is associated with poor survival in HD patients, and such associations persist 
across different PTH strata (Kalantar-Zadeh et al., 2006). An ALP >80 U/l predicted early 
mortality, and it remained significant even after adjustment for iPTH (Chua et al., 2014). 
Raised ALP is linked to vascular health. The raised ALP caused vascular calcification by an 
increase in the hydrolysis of pyrophosphate, which is a potent inhibitor of vascular 
calcification (Lomashvili et al., 2008). 
 
2.3.2.3 Albumin 
Low albumin has been consistently shown to be associated with death in ESRD 
(Chua et al., 2014). 33% of death in the first 90 days was associated with hypoalbuminemia 
in the United States. Reduction of serum albumin per 2 g/L associated with 21% increase in 
mortality in first 90 days and 12% during the 12-24 month period. There were 5-fold higher 
infection-related mortality and 2-fold higher cardiovascular mortality in patients with low 
serum albumin (Lukowsky et al., 2012).  
In an earlier similar study in 2007, albumin levels <35 g/L was associated with 
increased risk of mortality during the first 120 days (Bradbury et al., 2007). Low albumin 
level is frequently related to anorexia and malnutrition. However, CKD studies suggested 
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different and more complex etiologies such as acidosis and chronic inflammation (Eustace et 
al., 2004). The relationship between raised inflammatory markers, low albumin, and 
cardiovascular events in CKD patients has recently been described (Soriano et al., 2007). 
Low albumin levels also represent the severity of acute illnesses during the dialysis initiation 
as it is a negative acute-phase reactant and this usually implies poorer prognosis. 
 
2.3.2.4 Calcium, phosphate and calcium-phosphate products 
It is a recognized risk factor in the literature that calcium phosphate product had a 
significant association with the vascular burden. High calcium phosphate product adversely 
affects mortality. This association is present even before initiation of dialysis (Cherukuri and 
Bhandari, 2009).   
The changes in biochemical markers of CKD–MBD contribute to the high mortality 
in patients with CKD. A study conducted in the Europe country had shown that among 
patients whose mineral bone disorder markers were within The National Kidney 
Foundation's Kidney Disease Outcomes Quality Initiative (KDOQI) target range had lowest 
risk of mortality (Floege et al., 2010). This was also supported by another study in South 
America where they confirmed that patients are best maintained at the target ranges as 
defined by both KDOQI and KDIGO and levels too low or too high are associated with an 
increased mortality. The comfort of having these serum parameters maintained in the trough 
of this U-shaped biochemical mortality relationship is shown figuratively in the model 
(Kalantar-Zadeh et al., 2006). 
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Figure 2.0: U-shaped biochemical mortality relationship 
Source: CKD–MBD: comfort in the trough of the U  
Nephrology Dialysis Transplantation, Volume 26, Issue 6, 1 June 2011, Pages 1764–
1766,https://doi.org/10.1093/ndt/gfr205 
 
A high calcium level have strong prognostic value for long-term mortality base on 
baseline analysis, whereas a low calcium level has little prognostic value despite its positive 
association with mortality, when all values of calcium are updated over time (Floege et al., 
2010). 
The evidence for serum phosphate seems to suggest that either a low or a high level 
is a risk factor for mortality (Floege et al., 2010). With respect to low phosphate levels, this 
seems clinically plausible since a low serum phosphate is a marker for malnutrition, a known 
predictor of mortality (Qureshi et al., 2002). This relation persisted even after adjustment for 
serum albumin (de Mutsert et al., 2009), which suggests the possibility that the effect of 
serum phosphate on mortality is acting through another biological mechanism besides 
nutritional status.  
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Usually, serum phosphate is elevated in patients with CKD especially when GFR less 
than 30 ml/min. High phosphate may cause development and progression of secondary 
hyperparathyroidism. When the product of serum calcium and phosphorus is elevated this 
predisposes to metastatic calcification. Patients are prescribed with phosphate binders with 
the advice of restriction of dietary phosphate to reduce serum phosphate. All these 
conditions lead to morbidity and  mortality in ESRD patients (Block et al., 1998; Melamed 
et al., 2006; Noordzij et al., 2005).  
 
The relationship between bone mineral parameters and mortality was explained in 
few laboratory and clinical studies through a biological mechanism. The high levels of 
serum phosphate activate the osteoblastic activity of the smooth muscle cells in the vessels 
which subsequently promote mineralization of the vascular system (Jono et al., 2000; Moe 
and Chen, 2004).  
There a high rate of coronary calcification among the young hemodialysis patients. 
This is associated with high calcium intake (Goodman et al., 2000). This might be one of the 
explanations of mortality in patients with high serum calcium. This is shown by Raggi et al. 
where higher serum calcium and phosphate levels are associated with coronary calcification, 
in addition to a cross-sectional association of calcification with myocardial infarction (MI), 
angina and claudication (Raggi et al., 2002).  
During the first 120 days of hemodialysis, a phosphate level of <1.13 mmol/L were 
significantly associated with mortality. Between 121 and 365 days, calcium level >2.37 
mmol/L were associated with high mortality risk. A calcium level <2.1 mmol/L was 
associated with lower risk for mortality. 
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2.3.2.5 Serum intact parathyroid hormone (iPTH) 
Some studies showed that high levels of serum phosphate, calcium-phosphate 
product, or intact parathyroid hormone (iPTH) are associated with mortality or 
cardiovascular disease (Block et al., 1998; Ganesh et al., 2001; Stack and Bloembergen, 
2001). while others showed implication with low iPTH levels (Avram et al., 2001; Guh et 
al., 2002). These have led to confusions. 
Recently, there a description of the association between high ALP with poor survival in HD 
patients and this association persist across different PTH strata. PTH levels above 300 pg/ml 
were associated with high mortality risk among maintenance HD patients. Compared to the 
iPTH levels 150 to 300 pg/ml (reference) group, iPTH 300 to 600 pg/ml group were 
incrementally associated with higher mortality risk. However, PTH levels above 600 pg/ml, 
did not show an increase in mortality but still associated with high death risk. This can be 
explained as most dialysis patients with very high PTH levels usually received higher than 
usual doses of the active vitamin D analogs (Kalantar-Zadeh et al., 2006). This was also 
supported by Floege et al., 2010 where they found U-shaped association between iPTH and 
mortality where low iPTH levels <75 pg/mL are a potential risk factor for mortality. 
Those with lowest iPTH levels at the start of dialysis are most likely to die (Avram et 
al., 2001; Guh et al., 2002), and high serum iPTH levels have an adverse impact (Block et 
al., 1998; Ganesh et al., 2001).  
Higher values of serum phosphate and the highest categorical level of calcium-
phosphate product as well as the constellation of the three parameters calcium, phosphate, 
and iPTH, were a statistically significant predictor of mortality. Patients on dialysis for <6 
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months seem to have a worse outcome when their phosphate is high, irrespective of whether 
the calcium and iPTH are high or low, with the highest risk being identified in those with 
low iPTH, high calcium, and high phosphate. The lowest risk is associated with higher iPTH 
levels, with normal serum calcium and phosphate levels. Therefore, it is important to 
maintain some iPTH activity to enable buffering of calcium salts and this reflects an active 
bone turnover (Stevens et al., 2004). A lower value of iPTH indicates low bone turnover 
(adynamic bone disease) however, not all patients with low iPTH have low bone turnover, it 
was patients with low iPTH with raised serum calcium and phosphate levels who had the 
highest risk of mortality. The constellation of this parameters are better markers for adverse 
outcomes and low bone turnover compare to iPTH alone.   
Thus the interpretation of serum iPTH is important within the context of the duration 
of dialysis and levels of calcium and phosphate. 
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2.4 INTRODUCTION TO STUDY AREA 
  
          Kelantan is one of the thirteen states in Malaysia. It consists of ten districts including 
its capital, Kota Bharu. The district of Kota Bharu covers an area of about 410 square 
kilometers and has a population of about 1.83 million. The majority (95%) is Malay with a 
small percentage of Chinese and Indian. Two tertiary hospitals namely Hospital Raja 
Perempuan Zainab II (HRPZ II) and Hospital Universiti Sains Malaysia (HUSM) are located 
in this district. HRPZ II is a government general hospital while HUSM is a teaching hospital. 
Apart from receiving patients from Kota Bharu area itself, these two tertiary hospitals also 
receive patients referred from other district hospitals. 
 In relation to hemodialysis, Kelantan has 31 hemodialysis centers. Besides the two 
tertiary hospitals, eight districts hospitals also have hemodialysis facility which includes 
Hospital Kuala Krai, Hospital Tanah Merah, Hospital Pasir Mas, Hospital Machang, 
Hospital Tumpat, Hospital Tengku Anis, Hospital Jeli, and Hospital Gua Musang. Another 
two clinics which also has hemodialysis facilities are Mahligai and Chiku 3. These 10 are all 
government-sponsored hemodialysis facilities.  
 There were 20 private or NGO sponsored hemodialysis fascilities. A total of 640 
patients currently undergoing hemodialysis in the government sponsored hemodialysis unit 
in Kelantan for the year of 2016 while another 185 patients awaiting for hemodialysis 
placement. 
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CHAPTER 3 
OBJECTIVES, RESEARCH QUESTIONS & HYPOTHESIS 
 
3.1 OBJECTIVES 
 
3.1.1 General Objective  
To identify prognostic factors affecting 1-year mortality after initiating hemodialysis in 
newly diagnosed End Stage Renal Disease (ESRD) patients in the state of Kelantan, 
Malaysia. 
 
3.1.2 Specific Objectives 
1. To describe demographic profile of incident patients initiated on hemodialysis. 
 
2. To estimate survival probability within one year in End Stage Renal Disease patients 
initiated on hemodialysis in Kelantan. 
 
3. To identify prognostic variables for mortality during 1 year follow up of a patient 
with End Stage Renal Disease initiated on hemodialysis in Kelantan. 
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3.2 RESEARCH QUESTIONS 
1. What are the demographic profiles of End Stage Renal Disease patients in Kelantan? 
 
2. What are the overall survival probabilities of ESRD patients during the first-year 
initiation of hemodialysis? 
 
3. What are the risk factors that contribute to the first year mortality in incident patients 
initiated on hemodialysis? 
 
4. How significant is the above risk factors in contributing mortality in incident patients 
initiated on hemodialysis? 
 
 
 
 
 
 
 
 
 
